Compare LXEO & FLGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LXEO | FLGT |
|---|---|---|
| Founded | 2017 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Medical Specialities |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 731.3M | 867.4M |
| IPO Year | 2023 | 2016 |
| Metric | LXEO | FLGT |
|---|---|---|
| Price | $6.84 | $14.65 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 10 | 3 |
| Target Price | $18.60 | ★ $28.33 |
| AVG Volume (30 Days) | ★ 644.7K | 486.9K |
| Earning Date | 01-01-0001 | 06-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 75.08 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $654,000.00 | ★ $18,730,000.00 |
| Revenue This Year | N/A | $10.66 |
| Revenue Next Year | N/A | $12.17 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.45 | $13.46 |
| 52 Week High | $10.99 | $31.04 |
| Indicator | LXEO | FLGT |
|---|---|---|
| Relative Strength Index (RSI) | 44.15 | 20.89 |
| Support Level | $6.15 | N/A |
| Resistance Level | $7.72 | $19.96 |
| Average True Range (ATR) | 0.43 | 0.99 |
| MACD | 0.11 | -0.83 |
| Stochastic Oscillator | 57.00 | 9.87 |
Lexeo Therapeutics Inc is a clinical-stage genetic medicines company committed to transforming healthcare by applying pioneering science to fundamentally alter how diseases are treated. The company focuses on preclinical and clinical stage gene therapies, specifically hereditary and acquired diseases with high unmet needs, which represent its sole business segment.
Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. The company is engaged in laboratory services business and a therapeutic development business. The laboratory services business which generates key revenue includes, technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a broad range of cancers. The geographical segments are the United States, which generates the vast majority of the revenue; and Foreign.